ReviewFrontiers in pharmacology2025

MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck.

Dennis Christoph Harrer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.